UNSPSC 51181546: Glisamuride

This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T4C1IE36L0. European Medicines Agency schedules Glisamuride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07929MIG. Glisamuride generally arises in the molecular formula C23H31N5O4S.

UNSPSC 51181546 Glisamuride, a Commodity code, encompasses diabetes and metabolic-disorder pharmaceuticals that state and local government health systems, correctional facilities, and procurement cooperatives source through wholesaler networks. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, exemplifies current buying patterns: manufacturers supply generic multi-source pharmaceuticals and OTC products to state and local members across multiple jurisdictions through authorized drug wholesalers under master agreements. Vendors competing under this code must meet cGMP certification and Drug Supply Chain Security Act compliance, maintain relationships with at least two of three specified wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, Morris & Dickson Co.), and accept chargeback and EDI systems. Pricing evaluation emphasizes price competitiveness (75 percent weight), with secondary factors including fixed-price format compliance, administrative-fee acceptance (3 percent), and EDI capability. Insurance requirements include $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability per occurrence.

The MMCAP RFP (S1070000015802), due March 26, 2026, covers participating state and local facilities across Minnesota and Oregon with a two-year initial contract term effective July 1, 2026. Geographic activity concentrates in multistate cooperative-purchasing vehicles that serve state departments and local health agencies across the upper Midwest and Pacific Northwest. Manufacturers must supply detailed product information by NDC code and achieve marketplace availability by May 15, 2026; contract awards will be made to sole, dual, or multiple vendors depending on therapeutic category, product availability, and member need. Performance penalties range from $200 to $1,500 per violation for late reporting, missed onboarding, or class-of-trade denials. No specific award value or budget range is disclosed; vendors should assume per-unit pricing competition within existing state and local pharmaceutical consumption volumes across the MMCAP membership.